DANVERS, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced today that it has entered into a corporate partnership with Fenway Park and will be bringing its Impella Mobile Learning Lab to the historic baseball stadium tomorrow. The Mobile Learning Lab will be parked at Fenway for Boston-area physicians, clinicians and nurses to come onboard and learn about Impella®, the World’s Smallest Heart Pump.
To date, over 30,000 U.S. patients have been treated with Abiomed’s Impella devices since 2008, nearly enough individuals to fill Fenway Park, which has a capacity of 37,673 people. By the end of its fiscal year, Abiomed expects that it will have treated enough Impella patients to fill the entire park. To mark the 30,000 patient milestone, the Abiomed logo is featured next to the Green Monster in right-center field for the rest of the 2015 season and will also be placed in the stadium for the 2016 baseball season.
“We are delighted to form a partnership with this leader in the medical technology industry,” said Red Sox Executive Vice President/COO Sam Kennedy. “Abiomed is helping to recover hearts and save lives with its innovative technology and helping the Massachusetts economy by expanding its headquarters locally. We look forward to playing host to its Mobile Learning Lab at Fenway Park on August 12.”
“As a Massachusetts-based company since 1981, we are passionate Red Sox fans and are excited and honored to enter into this partnership with Fenway Park,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “We have reached an inflection point in our Company and we’re pleased to bring the Mobile Learning Lab to Boston – one of the leading healthcare innovation centers in the entire world.”
The Impella Mobile Learning Lab is a highly interactive, facilitated learning experience that enables hospital and health providers to learn more about protected percutaneous coronary intervention (PCI) procedures, such as balloon angioplasty and stenting, which re-open coronary arteries that are narrowed or blocked due to severe coronary artery disease (CAD), which is offered through the Impella 2.5 device. The Impella 2.5 heart pump is a minimally invasive device intended for temporary use by patients with severe symptomatic CAD and diminished (but stable) heart function who are undergoing a PCI procedure but are not candidates for surgical coronary bypass treatment.
The Mobile Learning Lab will be located at the corner of Van Ness Street and Yawkey Way from noon to 8 p.m. on August 12, 2015. During the event, staff from hospitals across Boston will have the opportunity to interact with the Impella technology through simulators and animations, and talk to a team of specialized Abiomed trainers.
Bob Pasquariella of Everett, Mass. experienced urgent heart failure and received Impella support. He is scheduled to attend the event and discuss his experience.
Earlier this summer, Abiomed announced a major expansion of its U.S. headquarters, doubling the footprint of its Danvers facility, with a specialized building design for new manufacturing and research capabilities and state of the art training facilities, and the creation of at least 100 new jobs in the state.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.